JP2022183993A - Composition for improving or repairing skin barrier function - Google Patents

Abstract

To provide a composition for improving or repairing a skin barrier function.SOLUTION: A composition for improving or repairing a skin barrier function contains α-fluoromethyl histidine or a derivative thereof as an active ingredient.SELECTED DRAWING: Figure 1

Description

The present invention relates to topical compositions, in particular compositions for improving or repairing skin barrier function.

Histamine is induced by the decarboxylation reaction of histidine, an amino acid, and has pharmacological effects such as hypotension, increased vascular permeability, smooth muscle contraction, vasodilation, and promotion of gland secretion. known to work (Non-Patent Document 1).

α-Fluoromethylhistidine (αFMH), together with α-hydrazinohistidine, histidine methyl ester and the like, is known as a compound that inhibits histamine biosynthetic enzymes. αFMH anti-ulcer agent (Patent Document 1), asthma remedy (Patent Document 2), hair restorer and hair growth inhibitor (Patent Document 3, Patent Document 4), and anti-inflammatory/analgesic agent (Patent Document 5) has been reported for use as In addition, α-hydrazinohistidine and histidine methyl ester also inhibit the formation of terminal glycation products, atherosclerosis and diabetes markers, protein aging inhibition, Maillard activity inhibition, tooth discoloration prevention, anti-gastric acid secretion agent, and skin irritation inhibitor. has been reported to be used as (Patent Documents 6 to 11).

Histamine has been reported to alter protein expression associated with the skin barrier (Non-Patent Document 2). However, there is no report verifying the effect of suppressing histamine biosynthesis in actual skin. In addition, improvement of the skin barrier by histamine _H1 receptor and _H2 receptor antagonists has been reported (Non-Patent Document 2). Various skin barrier function improving agents have been known so far (Patent Documents 12 to 15). There is also a report on improvement of hypersensitivity caused by damage to the skin barrier (epidermal barrier) (Patent Document 16).

JP-A-57-059812 JP-A-6-100446 Japanese Unexamined Patent Application Publication No. 2004-191106 Japanese Patent Publication No. 11-501035 JP-A-59-112917 Japanese Patent Publication No. 9-511492 Japanese Patent Publication No. 8-507516 Japanese Patent Publication No. 7-503713 JP-A-2-056413 JP-A-58-043970 Japanese Patent Publication No. 10-513452 JP-A-2008-1599 JP 2019-199437 A Japanese Patent Application Laid-Open No. 2020-203862 JP 2021-17447 A Japanese Patent Application Laid-Open No. 2004-107250

Masataka Satomi, Journal of Japan Society for Food Science and Engineering, Vol.57, 2010, No.8 Y. Ashida et al., The Journal of Investigative Dermatology, VOL.116, No.2, February 2001, pp 261-265

The present invention has been made in view of the above, and an object of the present invention is to provide a composition for improving or repairing skin barrier function. Another object of the present invention is to provide a composition for preventing, improving or treating hypersensitivity.

In view of the above problems, the present inventors conducted intensive studies and found that a composition containing α-fluoromethylhistidine (αFMH) or a derivative thereof as an active ingredient is useful for improving and repairing skin barrier function. rice field. They also found that a composition containing α-fluoromethylhistidine (αFMH) or a derivative thereof as an active ingredient is useful for preventing, improving or treating hypersensitivity. The present invention has been completed through further studies based on these findings.

That is, the present invention includes the aspects of the invention listed below.

[1-1] A composition for improving or repairing skin barrier function, containing α-fluoromethylhistidine or a derivative thereof as an active ingredient.

[1-2] A composition for preventing, improving or treating hypersensitivity, containing α-fluoromethylhistidine or a derivative thereof as an active ingredient.

[1-3] The composition according to [1-1] or [1-2], wherein the content of α-fluoromethylhistidine or derivative thereof is 1% by weight or more of the entire composition.

[1-4] The composition according to any one of [1-1] to [1-3], wherein the content of α-fluoromethylhistidine or derivative thereof is 3% by weight or more of the entire composition.

[1-5] The composition according to any one of [1-1] to [1-4], wherein the content of α-fluoromethylhistidine or derivative thereof is 6% by weight or more of the entire composition.

[1-6] The composition according to any one of [1-1] to [1-5], which is a pharmaceutical.

[1-7] The composition according to any one of [1-1] to [1-6], wherein the α-fluoromethylhistidine derivative is a pharmacologically acceptable salt thereof.

[1-8] The composition according to any one of [1-1] to [1-7], for use as an external composition.

[2-1] A method for improving or restoring skin barrier function, comprising administering to a subject a composition containing an effective amount of α-fluoromethylhistidine or a derivative thereof.

[2-2] A method for preventing, improving or treating hypersensitivity, which comprises administering to a subject a composition containing an effective amount of α-fluoromethylhistidine or a derivative thereof.

[2-3] The method according to [2-1] or [2-2], wherein the content of α-fluoromethylhistidine or derivative thereof is 1% by weight or more of the entire composition.

[2-4] The method according to any one of [2-1] to [2-3], wherein the content of α-fluoromethylhistidine or derivative thereof is 3% by weight or more of the entire composition.

[2-5] The method according to any one of [2-1] to [2-4], wherein the content of α-fluoromethylhistidine or derivative thereof is 6% by weight or more of the entire composition.

[2-6] The method according to any one of [2-1] to [2-5], wherein the composition is a pharmaceutical.

[2-7] The method of any one of [2-1] to [2-6], wherein the derivative of α-fluoromethylhistidine is a pharmacologically acceptable salt of α-fluoromethylhistidine.

[2-8] The method according to any one of [2-1] to [2-7], wherein the composition is an external composition.

[3-1] α-fluoromethylhistidine or a derivative thereof used as a pharmaceutical.

[3-2] The α-fluoromethylhistidine or derivative thereof according to [3-1], for use in improving or repairing skin barrier function.

[3-3] The α-fluoromethylhistidine or derivative thereof according to [3-1], for use in preventing, improving or treating hypersensitivity.

[3-4] The composition according to any one of [3-1] to [3-3], which is administered as a composition containing α-fluoromethylhistidine or a derivative thereof in an amount of 1% by weight or more of the total composition. α-fluoromethylhistidine or derivatives thereof.

[3-5] The composition according to any one of [3-1] to [3-4], which is administered as a composition containing α-fluoromethylhistidine or a derivative thereof in an amount of 3% by weight or more of the total composition. α-fluoromethylhistidine or derivatives thereof.

[3-6] The composition according to any one of [3-1] to [3-5], which is administered as a composition containing α-fluoromethylhistidine or a derivative thereof in an amount of 6% by weight or more of the total composition. α-fluoromethylhistidine or derivatives thereof.

[3-7] The α-fluoro according to any one of [3-1] to [3-6], wherein the derivative of α-fluoromethylhistidine is a pharmacologically acceptable salt of α-fluoromethylhistidine methylhistidine or its derivatives;

[3-8] The α-fluoromethylhistidine or derivative thereof according to any one of [3-4] to [3-6], wherein the composition is a composition for external use.

[4-1] Non-therapeutic use of α-fluoromethylhistidine or a derivative thereof for improving or repairing skin barrier function.

[4-2] Non-therapeutic use of α-fluoromethylhistidine or a derivative thereof in preventing or improving hypersensitivity.

[4-3] Use according to [4-1] or [4-2] as a composition containing α-fluoromethylhistidine or a derivative thereof in an amount of 1% by weight or more of the total composition.

[4-4] Use according to any one of [4-1] to [4-3] as a composition containing α-fluoromethylhistidine or a derivative thereof in an amount of 3% by weight or more of the total composition .

[4-5] Use according to any one of [4-1] to [4-4] as a composition containing α-fluoromethylhistidine or a derivative thereof in an amount of 6% by weight or more of the total composition .

[4-6] The use according to any one of [4-1] to [4-5], wherein the derivative of α-fluoromethylhistidine is a pharmacologically acceptable salt of α-fluoromethylhistidine.

[4-7] Use according to any one of [4-3] to [4-5], wherein the composition is an external composition.

[5-1] Use of α-fluoromethylhistidine or a derivative thereof for preparing a composition for use in improving or repairing skin barrier function.

[5-2] Use of α-fluoromethylhistidine or a derivative thereof for preparing a composition for use in preventing, improving or treating hypersensitivity.

[5-3] The use according to [5-1] or [5-2], wherein the content of α-fluoromethylhistidine or derivative thereof is 1% by weight or more of the entire composition.

[5-4] Use according to any one of [5-1] to [5-3], wherein the content of α-fluoromethylhistidine or derivative thereof is 3% by weight or more of the entire composition.

[5-5] Use according to any one of [5-1] to [5-4], wherein the content of α-fluoromethylhistidine or derivative thereof is 6% by weight or more of the entire composition.

[5-6] Use according to any one of [5-1] to [5-5], wherein the composition is a pharmaceutical.

[5-7] The use according to any one of [5-1] to [5-6], wherein the derivative of α-fluoromethylhistidine is a pharmacologically acceptable salt thereof.

[5-8] Use according to any one of [5-1] to [5-7], wherein the composition is a composition for external use.

According to the skin barrier function-improving or repairing composition of the present invention, weakened skin barrier function can be improved, and the effect can be obtained continuously. In addition, according to the composition for prevention, improvement or treatment of hypersensitivity of the present invention, hypersensitivity reaction can be suppressed and its effect can be obtained continuously. In addition, while the inhibitory effect on spontaneous itching that occurs as a symptom is low, it can inhibit hypersensitivity to itching that occurs after receiving an external stimulus that normally does not cause itching.

FIG. 1 shows the changes in stratum corneum water content in mice treated with 1 wt%, 3 wt% and 6 wt% αFMH, 1 wt% diphenhydramine hydrochloride, petroleum jelly, and 0.3 wt% heparinoid. It is a graph which shows a daily change. Figure 2 shows transepidermal water loss ( 1 is a graph showing changes in transdermal epidermal loss (TEWL) over time. FIG. 3 is a graph showing daily changes in itch response in mice treated with 6 wt % αFMH. Figure 4 shows the itch hypersensitivity reaction (allonesis) in mice when treated with 1 wt%, 3 wt% and 6 wt% αFMH, 1 wt% diphenhydramine hydrochloride, petroleum jelly, and 0.3 wt% heparinoid. Alloknesis) is a graph showing changes over time. On the Y-axis, the case where the mouse scratched with its hind leg after applying non-invasive stimulation once with the experimental apparatus [von Frey filament (manufactured by Muromachi Kikai Co., Ltd.), target force: 0.07 g] was counted as 1, and the same The number of counts (allonesis score) when the operation was performed 15 times in total is shown. FIG. 5 is a graph showing the time course of itch hypersensitivity reaction (Alloknesis) in mice treated with 1 wt%, 3 wt% and 6 wt% αFMH, and 1 wt% diphenhydramine hydrochloride. On the Y-axis, the case where the mouse scratched with its hind leg after applying non-invasive stimulation once with the experimental apparatus [von Frey filament (manufactured by Muromachi Kikai Co., Ltd.), target force: 0.07 g] was counted as 1, and the same The number of counts (allonesis score) when the operation was performed 15 times in total is shown. FIG. 6 is a diagram showing a timeline of tests in Examples 1 and 2. FIG. 7 is a diagram showing stimulation sites of mice in Examples 1 and 2. FIG.

In one aspect, the present invention provides a composition for improving or repairing skin barrier function containing α-fluoromethylhistidine or a derivative thereof as an active ingredient. The skin barrier function is a function carried out by the stratum corneum and epidermis of the skin. It is a function to prevent intrusion into In one embodiment, the skin barrier function can be evaluated in units of (g/m ² h) by measuring transepidermal water loss (TEWL) under non-perspiring conditions (Japan Cosmetic Technician ed., Cosmetic Encyclopedia, Maruzen Co., Ltd., 2005, pp. 83-84).

In one aspect, the present invention provides a composition for preventing, improving or treating hypersensitivity containing α-fluoromethylhistidine or a derivative thereof as an active ingredient. As used herein, hyperesthesia means a symptom caused by increased sensitivity to weak external stimuli that normally do not cause itching, particularly external stimuli to the epidermis, and is also called hypersensitivity to itching. Hypersensitivity symptoms in the present invention include symptoms associated with dermatitis. Symptoms associated with dermatitis include pain and itching in the epidermis, particularly those with itching as the chief complaint. Hypersensitivity in the present invention is measured by an allonesis (a condition in which stimuli that normally do not produce itching cause itching) score.

In one aspect of the invention, the derivative of αFMH is a pharmacologically acceptable salt of αFMH. "Pharmacologically acceptable salt" means, for example, inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide or phosphate, oxalate, malonic acid Salt, Citrate, Fumarate, Lactate, Malate, Succinate, Tartrate, Acetate, Trifluoroacetate, Maleate, Gluconate, Benzoate, Ascorbate, Glutaric Acid salt, mandelate, phthalate, methanesulfonate (mesylate), ethanesulfonate, benzenesulfonate, p-toluenesulfonate (tosylate), camphorsulfonate, aspartate , organic acid salts such as glutamate or cinnamate, salts with organic bases such as triethylamine salts, diisopropylethylamine salts, ethanolamine salts, morpholine salts, piperidine salts or dicyclohexylamine salts, basic amino acids such as arginine or lysine or a salt with an inorganic base such as a lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt, ammonium salt, aluminum salt or zinc salt.

In one aspect of the invention, the derivative of αFMH may be in the form of a prodrug of αFMH. "Prodrug" means a compound that can be converted in vivo to αFMH or a pharmacologically acceptable salt thereof.

Prodrugs of αFMH include compounds in which the carboxy group of αFMH is esterified or amidated. Specifically, the carboxy group of αFMH is a (C _1-6 alkoxy)carbonyl group such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, a phenoxycarbonyl group; group; dimethylaminomethoxycarbonyl group; pivaloyloxymethoxycarbonyl group, (C _1-6 alkyl)carbonyloxy(C _1-6 alkyl)carbonyl group such as acetyloxymethoxycarbonyl group; methoxycarbonyloxymethoxycarbonyl group, ethoxy (C _1-6 alkoxy)carbonyloxy(C _1-6 alkoxy)carbonyl groups such as carbonyloxyethoxycarbonyl group, isopropoxycarbonyloxymethoxycarbonyl group, tert-butoxycarbonyloxymethoxycarbonyl group; phthalidyloxycarbonyl group, ( Compounds substituted with 5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonyl group, cyclohexyloxycarbonylethoxycarbonyl group and methylaminocarbonyl group are exemplified.

Also included are compounds in which the amino group of αFMH is acylated, alkylated, or phosphorylated. Specifically, the amino group of αFMH is a (C _1-6 alkyl)carbonylamino group such as an acetylamino group, propionylamino group, butyrylamino group, isobutyrylamino group, pivaloylamino group, pentanoylamino group; (C _1-6 alkoxy)carbonylamino group such as butoxycarbonylamino group; eicosanoylamino group, carboxymethylmethylamino group, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonyl Compounds substituted with amino group, tetrahydrofuranylamino group, pyrrolidylmethylamino group, pivaloyloxymethylamino group and t-butylamino group are exemplified.

The composition of the present invention can be used as a composition for improving or repairing skin barrier function mixed with a pharmaceutically acceptable carrier, or as a composition for preventing, improving or treating hypersensitivity, for example, It can be administered parenterally in the form of injections, suppositories, skin external preparations and the like.

The compositions of the invention can be used for non-therapeutic applications. As used herein, "non-therapeutic use" means use that does not involve medical intervention, i.e., does not include use that treats humans. More specifically, non-therapeutic uses are meant not to include uses for administering treatments to humans by, for example, a physician or person under the direction of a physician.

The external preparation for skin of the present invention includes cosmetics, quasi-drugs, and pharmaceuticals for external use. Up press powder, blusher, white powder, lipsticks, facial cleanser, body shampoo, slimming agent, hair shampoo, hair rinse, treatment, soap, etc., and cosmetics such as bath agents; creams, lotions , gels, emulsions, liquids, poultices, patches, liniments, aerosols, ointments, and packs, but are not limited to these.

In addition to the active ingredient according to the present invention, external skin preparations may contain ingredients used in external skin preparations, such as oily ingredients, surfactants (synthetic or natural), moisturizers, thickeners, preservatives and sterilizers. Agents, powder components, ultraviolet absorbers, antioxidants, pigments, perfumes, etc. can be appropriately blended as needed. When these additives are contained in the external preparation for skin of the present invention, the content thereof may be appropriately set according to the type of additive used. In addition, other physiologically active ingredients can be combined and blended as long as the effectiveness and features of the present invention are not impaired.

The dosage form of the external preparation for skin is not particularly limited as long as it can be applied transdermally, and may be liquid, solid, semi-solid (cream, gel, ointment, paste), foam, or the like. may The composition of the present invention may be an emulsified formulation such as an oil-in-water emulsion formulation or a water-in-oil emulsion formulation, or may be a non-emulsified formulation such as a solubilized formulation or an aqueous ointment.

The composition for improving or repairing skin barrier function of the present invention is used for purposes such as repairing lowered skin barrier function, maintaining/improving healthy skin barrier function, and suppressing deterioration of skin barrier function. The composition for prevention, improvement or treatment of hypersensitivity of the present invention is used for prevention, improvement or treatment of epidermal hypersensitivity such as itching or pain.

The concentration of α-fluoromethylhistidine in the composition of the present invention is 1% by weight or more, preferably 3% by weight or more, and more preferably 6% by weight or more.

The compositions of the invention can be applied to specific areas of the body. For example, it can be applied to the head, face, neck, legs, feet, arms, hands, torso, belly or back.

Example 1: Evaluation test of skin barrier repair effect A 10% by weight sodium dodecyl sulfate (SDS) solution was prepared using 70% by weight ethanol as a solvent, and Hos: HR-1 hairless mice (Hoshino Experimental Animal Breeding Center) ( 7-week-old males, 6-8/group) were applied with a pipette to the rostral dorsum of 50 μL once daily for 4 consecutive days. SDS dermatitis was observed on the 2nd day when the experiment start date was the 0th day. After 3 hours from the application of the 10% by weight SDS solution on the second day, each evaluation drug (αFMH (MedKoo Biosciences, Inc.), diphenhydramine hydrochloride (Asgen Pharmaceutical Co., Ltd.) using 50% by weight ethanol as a solvent was applied to the SDS application site. ), vaseline (Nikko Rica Co., Ltd.), and a heparin-like substance (Api Co., Ltd.) solution was applied. 30 μL of the drug was applied to the rostral dorsum once a day for two consecutive days using a pipette or syringe. Before applying the SDS solution on each day (22 to 24 hours after the application of the SDS solution on the previous day), the moisture content of the stratum corneum was measured using a Moisture Checker (registered trademark) (Scalar Corp.) as an index of skin dryness. .), and transepidermal water loss (TEWL) as an index of skin barrier was measured using a Vapometer (Keystone Scientific Co., Ltd.) to measure itching in the absence of noninvasive stimulation. For the purpose of evaluating the degree of scratching, the behavior of scratching the SDS-applied site with the hind limbs of mice was video-captured in an unmanned environment, and the video data was observed after the video-capturing for evaluation. The timeline for SDS solution application, evaluation drug application, and measurement is shown in FIG. The test results are shown in Tables 1-2 below and Figures 1-2. From the results of the stratum corneum moisture content test, there was no difference in the effect of each evaluation drug on the stratum corneum moisture content, and the moisturizing ability was the same.

経表皮水分蒸散量（ＴＥＷＬ）の試験結果から、αＦＭＨの投与マウスにおいて経皮水分蒸散量の低減効果、すなわち皮膚バリア修復効果が確認された。１重量％αＦＭＨの投与マウスにおいてその効果は既存保湿医薬品（ワセリン、ヘパリン類似物質）や既存外用抗ヒスタミン薬（ジフェンヒドラミン塩酸塩）よりも優れていた。

From the test results of transepidermal water loss (TEWL), it was confirmed that αFMH-administered mice had a reduction effect on transepidermal water loss, that is, a skin barrier repair effect. In mice administered 1% by weight αFMH, the effect was superior to that of existing moisturizing drugs (petrolatum, heparin-like substances) and existing topical antihistamines (diphenhydramine hydrochloride).

実施例２：痒み反応及び痒み過敏反応の評価試験
実施例１と同様に、７０重量％エタノールを溶媒とする１０重量％ドデシル硫酸ナトリウム（ＳＤＳ）溶液を準備し、Ｈｏｓ：ＨＲ－１ヘアレスマウス（株式会社 星野試験動物飼育所）（７週齢の雄、６―８匹／群）の吻側背部に１日１回、４日間続けて塗布した。実験開始日を第０日とした時、第２日にＳＤＳ皮膚炎が観察された。第２日の１０重量％ＳＤＳ溶液の塗布から３時間経過後、ＳＤＳ塗布部位に各評価薬物（αＦＭＨ、ジフェンヒドラミン塩酸塩、ワセリン、ヘパリン類似物質）を塗布した。薬物塗布は１日１回、２日間連続で行った。各日のＳＤＳ溶液塗布前に、実験器具［von Frey filament（室町機械株式会社製）（室町機械株式会社製）、ターゲットフォース：０．０７ｇ］を用いて非侵襲的な刺激をマウスの吻側背部のＳＤＳ皮膚炎の炎症周囲（図７参照）に加え、刺激した部位およびその周囲を後肢で引っ掻くか否かで知覚過敏反応を評価した。また、ＳＤＳ皮膚炎による自発的な痒みが発生するかについて、非侵襲的な刺激がない状態でのマウスの後肢によるＳＤＳ塗布部位への掻破行動を、無人環境下でビデオ撮影し、撮影後に動画データを観察することにより評価した。ＳＤＳ溶液塗布、評価薬物塗布、及び測定のタイミングを図６に示す。痒み反応の試験結果は表３及び図３に示されている。試験結果から、αＦＭＨの投与はマウスの痒み反応に影響を及ぼさないことが確認された。具体的には、６重量％αＦＭＨを投与したマウスにおいて、第３日には掻破回数が減少したが、第４日ではその痒み抑制効果が認められなかったことからαＦＭＨの鎮痒作用は小さいことが示唆された。

Example 2: Evaluation test of itch reaction and itch hypersensitivity reaction In the same manner as in Example 1, a 10% by weight sodium dodecyl sulfate (SDS) solution in 70% by weight ethanol was prepared, and Hos: HR-1 hairless mice ( Hoshino Laboratory Animal Breeding Co., Ltd.) (7-week-old males, 6-8 animals/group) were applied to the rostral dorsal region once a day for 4 consecutive days. SDS dermatitis was observed on the 2nd day when the experiment start date was the 0th day. Three hours after the application of the 10% by weight SDS solution on the second day, each evaluation drug (αFMH, diphenhydramine hydrochloride, petrolatum, heparin-like substance) was applied to the SDS-applied site. Drug application was performed once a day for two consecutive days. Before applying the SDS solution on each day, non-invasive stimulation was applied to the rostral side of the mouse using an experimental device [von Frey filament (manufactured by Muromachi Kikai Co., Ltd.) (manufactured by Muromachi Kikai Co., Ltd.), target force: 0.07 g]. Hypersensitivity reaction was evaluated by scratching the stimulated site and its surroundings with the hind leg in addition to the area around the inflammation of SDS dermatitis on the back (see FIG. 7). In addition, to determine whether spontaneous itching due to SDS dermatitis occurs, the behavior of scratching the SDS-applied site with the hind limbs of mice in the absence of non-invasive stimulation was video-recorded in an unmanned environment, and then video-recorded. It was evaluated by observing the data. FIG. 6 shows the timing of SDS solution application, evaluation drug application, and measurement. The results of the itch response test are shown in Table 3 and FIG. The test results confirmed that administration of αFMH had no effect on the itch response of mice. Specifically, in mice to which 6% by weight of αFMH was administered, the number of scratchings decreased on the third day, but no antipruritic effect was observed on the fourth day, suggesting that αFMH has a small antipruritic effect. It was suggested.

知覚過敏反応の試験結果を表４及び図４に示す。試験結果から、αＦＭＨに知覚過敏抑制効果があり、その効果は１重量％αＦＭＨにおいて、既存保湿医薬品（ワセリン、ヘパリン類似物質）や既存外用抗ヒスタミン薬（ジフェンヒドラミン塩酸塩）よりも優れていることが確認された。３重量％及び６重量％αＦＭＨで顕著な効果が見られた。

Table 4 and FIG. 4 show the results of the hypersensitivity test. From the test results, αFMH has an effect of suppressing hypersensitivity, and the effect is superior to existing moisturizing drugs (Vaseline, heparin-like substances) and existing topical antihistamines (diphenhydramine hydrochloride) at 1% by weight of αFMH. confirmed. Significant effects were seen at 3 wt% and 6 wt% αFMH.

実施例３：知覚過敏反応の評価試験
実験開始日を第０日とし、第２日の１０重量％ＳＤＳ溶液の塗布から３時間経過後、Ｈｏｓ：ＨＲ－１ヘアレスマウス（株式会社 星野試験動物飼育所）（７週齢の雄、６―８匹／群）のＳＤＳ塗布部位に各評価薬物（αＦＭＨ、ジフェンヒドラミン塩酸塩）を塗布した。その塗布直前と塗布から３０分おきにタッチテストを実施した。具体的には、塗布直前、塗布３０分後、６０分後、９０分後、１２０分後の５時点で、実験器具［von Frey filament（室町機械株式会社製）、ターゲットフォース：０．０７ｇ］を用いて非侵襲的な刺激をマウスの吻側背部のＳＤＳ皮膚炎の炎症周囲（図７参照）に加え、刺激した部位およびその周囲を後肢で引っ掻くか否かを、無人環境下でビデオ撮影し、撮影後に動画データを観察することにより評価した。試験結果を表５及び図５に示す。試験結果から、１重量％αＦＭＨは塗布３０分後から知覚過敏抑制効果を示し、その効果は既存外用抗ヒスタミン薬（ジフェンヒドラミン塩酸塩）よりも優れていることが確認された。

Example 3: Evaluation test of hypersensitivity reaction The experiment start date was day 0, and after 3 hours from the application of the 10 wt% SDS solution on day 2, Hos: HR-1 hairless mice (Hoshino Test Animal Breeding Co., Ltd. Each evaluation drug (αFMH, diphenhydramine hydrochloride) was applied to the SDS-applied site of (7-week-old male, 6-8/group). A touch test was performed immediately before the application and every 30 minutes after the application. Specifically, immediately before application, 30 minutes after application, 60 minutes, 90 minutes, and 120 minutes after application, the laboratory equipment [von Frey filament (manufactured by Muromachi Kikai Co., Ltd.), target force: 0.07 g] was used to apply non-invasive stimulation to the area around the inflammation of SDS dermatitis on the rostral back of the mouse (see Fig. 7), and whether or not the stimulated site and its surroundings were scratched with the hind limbs was filmed in an unmanned environment. It was evaluated by observing the moving image data after shooting. The test results are shown in Table 5 and FIG. From the test results, it was confirmed that 1% by weight αFMH showed an antihypersensitivity effect from 30 minutes after application, and that the effect was superior to the existing topical antihistamine (diphenhydramine hydrochloride).

Claims (6)

A composition for improving or repairing skin barrier function, containing α-fluoromethylhistidine or a derivative thereof as an active ingredient. A composition for preventing, improving or treating hypersensitivity, containing α-fluoromethylhistidine or a derivative thereof as an active ingredient. 3. The composition according to claim 1, wherein the content of α-fluoromethylhistidine or derivative thereof is 1% by weight or more of the total composition. A composition according to any one of claims 1 to 3, which is a medicament. A composition according to any one of claims 1 to 4, wherein the derivative of α-fluoromethylhistidine is a pharmacologically acceptable salt thereof. A composition according to any one of claims 1 to 5, for use as an external composition.

Images